Business Wire

ADVA

15.9.2022 09:01:51 CEST | Business Wire | Press release

Share
ADVA launches auto-tunable transceiver to help operators easily scale access networks to 25G

ADVA (FSE: ADV) today launched its AccessWave25™, empowering network operators to easily migrate their 10Gbit/s access infrastructure to 25Gbit/s connectivity without a significant increase in footprint or major changes to the existing optical layer. The pluggable device answers the urgent need for higher bandwidth services in mobile X-Haul, cable access and wholesale networks. Operators can now slot the AccessWave25 into any standard-based SFP28 port for an instant capacity upgrade without replacing existing demarcation or aggregation devices. Using patent-pending distance optimization technology, the device also extends 25Gbit/s DWDM reach to 40km, and its G.metro auto-tuning technology reduces provisioning efforts and simplifies operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005787/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s AccessWave25™ offers an easy route to 25G DWDM connectivity in access networks without any major upgrades. (Photo: Business Wire)

“Our AccessWave25 is the key to unlocking more bandwidth at the edge. Now network operators have an easy, low-cost way to address soaring bandwidth consumption that doesn’t require extra real estate or cause major disruption to services. And as well as boosting capacity, the AccessWave25 offers a substantial increase in reach. While today’s solutions can’t go beyond 15km, our new pluggable device uses PAM4 modulation and direct-detection technology to support data transport up to 40km,” said Christoph Glingener, CEO of ADVA. “Simple to deploy and ideally suited for outdoor use, our AccessWave25 device will be the foundation for the next generation of optical access networks.”

ADVA’s AccessWave25 plug enables the seamless upgrade of fiber-based access networks. Host-agnostic and with a standardized SFP28 form factor, it empowers operators to instantly connect switches, routers and many other devices to DWDM open line systems. With full C-band tunable interfaces and G.metro self-tuning capabilities, the device reduces set-up time, minimizes human error and delivers operational cost savings. Network operators can also use the G.metro communication channel to remotely monitor the status and health of plugs for easy troubleshooting of any issues. Using less than 3 watts and with an I-temp hardened design, the AccessWave25 is perfect for deployment in a wide range of outdoor settings.

“The latest addition to our pluggable technology portfolio answers the most urgent needs of our customers in a wide range of industries. From the core to the metro to access networks, our product range offers a plug for almost every situation,” commented Saeid Aramideh, VP of business development at Optical Engines, ADVA. “OurAccessWave25 is a vital addition to our AccessWave family of pluggable devices and features our latest G.metro technology. Either with a third-party OLS or with our turnkey FSP 3000 solution for passive optical access networks, our pluggable technology provides the tools for tackling relentless growth in data consumption as well as the ever-changing demands of optical access networks.”

Further details on the ADVA AccessWave25™ are available in these slides: https://adva.li/accesswave25-slides.

A supporting product video is also available here: https://youtu.be/bcV06nMJ3_c.

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005787/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye